# Bone Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bone-therapeutics

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.bonetherapeutics.com
- Total disclosed funding: $8.2M
- Latest round: Series D (Jan 28, 2013)
- Investors on record: 3

## About

Founded in 2006 and based in Belgium, Bone Therapeutics SA, operates as a bone cell therapy company that develops and provides allogeneic cell therapy solutions using bone-forming cells. In November 2020, Catalent, Inc., a portfolio company of Leonard Green & Partners, acquired Bone Therapeutics SA for EUR 12 million. As of 2023, the company is led by its CEO, Miguel Forte, and operates a subsidiary, Skeletal Cell Therapy Support SA (SCTS).

Bone Therapeutics offers various cell therapy products, including ALLOB, and an enhanced viscosupplement made from mesenchymal stromal cells (MSC), for orthopedics and bone diseases. The company also provides a stem cell-based technology platform to cater to pre-clinical programs in immunomodulation and clinical development for orthopedic conditions.

## Funding rounds

- Series D, Jan 28, 2013, $8.2M — Life Sciences Research Partners, BAMS Angels Fund, Nausicaa Ventures

## Investors

- Life Sciences Research Partners — Series D
- BAMS Angels Fund — Series D
- Nausicaa Ventures (https://capitalatlas.ai/funds/nausicaa-ventures) — Series D